IGM Biosciences, Inc. (IGMS) Covered Calls

You can sell covered calls on IGM Biosciences, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for IGMS (prices last updated Fri 4:16 PM ET):

IGM Biosciences, Inc. (IGMS) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
9.40 +1.75 9.35 12.00 467K - 0.3
Covered Calls For IGM Biosciences, Inc. (IGMS)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
May 17 10 0.50 11.50 -13.0% -215.7%
Jun 21 10 1.80 10.20 -2.0% -12.8%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Extended Business Description

IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19; and strategic research collaboration and license agreement with AbCellera to discover and develop IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.